SCHEMBL4070239

SCHEMBL4070239

COC(=O)Cc1cc(C)nc(OC)c1C#N

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.46
PKM P14618 2/20 0.46
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
MAPK8 P45983 1/20 0.44
MAPK9 P45984 1/20 0.44
KDM4E B2RXH2 10/20 0.44
ALDH1A1 P00352 8/20 0.44
HPGD P15428 6/20 0.44
RECQL P46063 2/20 0.44
GAA P10253 4/20 0.43
GLA P06280 1/20 0.42
TSHR P16473 2/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 2/20 0.41
POLB P06746 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4064642 0.86 HSD17B10 (0.48) HSD17B10PKMCYP1A2CYP2C19KDM4E
SCHEMBL4069790 0.83 MAPK8 (0.41) HSD17B10PKMCYP1A2CYP2C19MAPK8
SCHEMBL16401095 0.82 RECQL (0.50) HSD17B10CYP1A2CYP2C19MAPK8MAPK9
SCHEMBL16401899 0.82 RECQL (0.50) HSD17B10CYP1A2CYP2C19MAPK8MAPK9
SCHEMBL4065725 0.82 MAPK8 (0.43) HSD17B10PKMMAPK8MAPK9KDM4E
SCHEMBL4075279 0.80 SQOR (0.62) HSD17B10KDM4EALDH1A1HPGDGAA
SCHEMBL4062552 0.78 ALDH1A1 (0.48) HSD17B10CYP1A2CYP2C19MAPK8MAPK9
SCHEMBL4073517 0.78 ADORA1 (0.48) PKMMAPK8MAPK9KDM4EALDH1A1
SCHEMBL4074987 0.78 TSHR (0.44) HSD17B10MAPK8MAPK9KDM4EALDH1A1
SCHEMBL4069316 0.78 RECQL (0.43) HSD17B10PKMCYP1A2CYP2C19MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601736-B2 Such as 3,4-dihydro-pyrano[3,4-c]pyridine-1-on; cytokine suppressive antiinflammatory drugs; analgesics SK CHEMICALS CO., LTD. (KR) 2009-10-13 US disclosed
EP-1706412-A4 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK CHEMICALS CO LTD (KR) 2009-03-18 EP disclosed
US-20070254909-A1 Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same SK CHEMICALS CO., LTD. (KR) 2007-11-01 US disclosed
EP-1706412-A1 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK Chemicals, Co., Ltd. (KR) 2006-10-04 EP disclosed
WO-2005063768-A1 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK CHEMICALS, CO., LTD. (KR) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254909-A1 Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same IL5, IL1B, P2RY4 HSD17B10 3499/4885PKM 972/4885CYP1A2 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.